Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.33 |
| ▸ | XPNPEP2 | O43895 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917334 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL3614287 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL5068781 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL3183947 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL16105109 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL22029235 | 1.00 | ATM (0.42) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL25300115 | 0.83 | DPP4 (0.37) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL16838680 | 0.83 | ATM (0.63) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL25261195 | 0.83 | DPP4 (0.37) | ATMDPP4DPP8DPP9PEPD | |
| SCHEMBL5211015 | 0.83 | ATM (0.63) | ATMDPP4DPP8DPP9PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584276-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-07-16 | — | — | EP | disclosed |
| WO-2024148274-A1 | COMPLEMENT INHIBITION | APELLIS PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024054926-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-03-14 | — | — | WO | disclosed |
| WO-2023086383-A1 | SELECT KRAS G12C INHIBITORS AND USES THEREOF | 1200 PHARMA LLC (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023030385-A1 | PYRIMIDINE-FUSED CYCLIC COMPOUND AND PREPARATION METHOD AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2023-03-09 | — | — | WO | disclosed |
| EP-3055302-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052264-A1 | SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-04-16 | — | — | WO | disclosed |